Lv21
178 积分 2024-10-27 加入
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
5小时前
待确认
Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
6小时前
已完结
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
12天前
已完结
Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs
13天前
已完结
Preclinical evaluation of abuse potential of the peripherally-restricted kappa opioid receptor agonist HSK21542
14天前
已完结
Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
25天前
已完结
RNA gene therapies offer hope for millions with high cholesterol
1个月前
已完结
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
1个月前
已完结
HDL as a Treatment Target: Should We Abandon This Idea?
1个月前
已完结
In vitro and in vivo Antibacterial Activity of Sudapyridine (WX-081) Combined with Other Drugs Against Mycobacterium abscessus
1个月前
已关闭
皖公网安备34019202002308
